SEELQ (Seelos Therapeutics) ROE % Adjusted to Book Value: Negative Equity% (As of Jun. 2024)


SEELQ Seelos Therapeutics Inc SEELQ
16 GF Score
Price $0.00
View Full Analysis

What is Seelos Therapeutics ROE % Adjusted to Book Value?

Seelos Therapeutics SEELQ 16 ROE % Adjusted to Book Value is Negative Equity% as of Jun. 2024. GuruFocus rates SEELQ with a GF Score™ of 16/100.

Seelos Therapeutics's ROE % for the quarter that ended in Jun. 2024 was Negative Equity. Seelos Therapeutics's PB Ratio for the quarter that ended in Jun. 2024 was N/A. Seelos Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was Negative Equity.

Seelos Therapeutics ROE % Adjusted to Book Value Related Terms

Seelos Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Seelos Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seelos Therapeutics ROE % Adjusted to Book Value Chart

Seelos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -45.09 -74.76 0.00 0.00

Seelos Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity 0.00 0.00 Negative Equity

SEELQ vs NTBLQ, EFTR, MTEM: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Seelos Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seelos Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's ROE % Adjusted to Book Value falls into.


SEELQ
16GF Score
Seelos Therapeutics Inc SEELQ
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seelos Therapeutics ROE % Adjusted to Book Value Calculation

Seelos Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Seelos Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Seelos Therapeutics (SEELQ) has a ROE % Adjusted to Book Value of Negative Equity% as of Jun. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Seelos Therapeutics and its competitors.
Is Seelos Therapeutics' ROE % Adjusted to Book Value too high?
Seelos Therapeutics' current ROE % Adjusted to Book Value is Negative Equity%. Overall, Seelos Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Seelos Therapeutics' ROE % Adjusted to Book Value compare to NTBLQ and EFTR?
Seelos Therapeutics' ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Seelos Therapeutics and its competitors. Seelos Therapeutics's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seelos Therapeutics stock overvalued right now?
Seelos Therapeutics (SEELQ) has a current ROE % Adjusted to Book Value of Negative Equity%. The current ROE % Adjusted to Book Value is Negative Equity%. Seelos Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Seelos Therapeutics (SEELQ), the current ROE % Adjusted to Book Value is Negative Equity% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seelos Therapeutics Business Description

Address 300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
16GF Score

Get the complete analysis for SEELQ

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price